C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A01K 67/027 (2006.01) A61K 9/66 (2006.01) A61K 38/17 (2006.01) A61P 29/00 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C07K 16/18 (2006.01) C12N 5/10 (2006.01) C12N 15/66 (2006.01) C12P 21/00 (2006.01) G01N 33/566 (2006.01) G01N 33/58 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2346217
The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction measured in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammatioin in the subject.
La présente invention concerne un peptide EN-RAGE humain isolé. Elle concerne également une méthode permettant de déterminer si un composé est capable d'inhiber l'interaction entre un peptide EN-RAGE et un peptide RAGE, laquelle méthode consiste: (a) à mélanger: (i) un peptide RAGE ou un peptide sRAGE ou un fragment de l'un quelconque de ces peptides, (ii) un peptide EN-RAGE ou un fragment dudit peptide, et (iii) le composé; (b) à mesurer le niveau d'interaction entre le peptide (a) (i) et le peptide (a) (ii) ; et (c) à comparer l'interaction mesurée au (b) avec le niveau d'interaction mesuré entre le peptide (a) (i) et le peptide (a) (ii) en l'absence du composé, ce qui permet de déterminer si le composé est capable d'inhiber l'interaction entre le peptide EN-RAGE et le peptide RAGE. Une réduction du niveau d'interaction en présence du composé indique que le composé est capable d'inhiber l'interaction. La présente invention concerne enfin une méthode d'inhibition de l'inflammation chez un sujet, qui consiste à administrer audit sujet un composé capable de perturber l'interaction entre le peptide EN-RAGE et le récepteur des produits terminaux de glycation avancée (RAGE) chez le sujet, inhibant ainsi l'inflammation.
Schmidt Ann Marie
Stern David
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
The Trustees Of Columbia University In The City Of New York
LandOfFree
Extracellular novel rage binding protein (en-rage) and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extracellular novel rage binding protein (en-rage) and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extracellular novel rage binding protein (en-rage) and uses... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2041268